Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

门冬胰岛素注射液 - NMPA Drug Approval Details

Approvals/NMPA/Insulin Aspart Injection

Approved

生物制品

Insulin Aspart Injection

宜昌东阳光长江药业股份有限公司🇨🇳 National Medical Products Administration

Approval Date: Oct 11, 2022
Approval ID: c5e18f1bf1fab4d0
Company: 宜昌东阳光长江药业股份有限公司
Type: 生物制品

Approval Details

Approval Id: c5e18f1bf1fab4d0
Approval Number: 国药准字S20220029
Generic Name: 门冬胰岛素注射液
Generic Name En: Insulin Aspart Injection
Drug Type: 生物制品
Dosage Form: 注射剂
Strength: 3ml：300单位（笔芯）
Reg Date: 2022-10-11
Company Name: 宜昌东阳光长江药业股份有限公司
Company Address: 湖北省宜昌宜都市滨江路38号
Production Company Name: 宜昌东阳光长江药业股份有限公司
Production Company Address: 湖北省宜昌宜都市东阳光3号工业园
Company Detail Path: /organization/hec-cj-pharm
Production Company Detail Path: /organization/hec-cj-pharm

Approved

Quick Info

Agency

NMPA

Country

🇨🇳

Approval Date

Oct 11, 2022

Approval ID

c5e18f1bf1fab4d0

Type

生物制品

Back to NMPA Approvals